The use of sGC modulators in HF was associated with a trend towards a significant difference in the incidence of SAEs compared to placebo (RR = 1.10, 95% CI 0.99–1.22, p = 0.07) (Fig. 8). The gene discussed is SGCB; the disease is hydrops fetalis.